
Jun 2, 2026
A Look At Recursion Pharmaceuticals (RXRX) Valuation As Shares Show Short Term Momentum
Recursion Pharmaceuticals (RXRX) is experiencing renewed investor interest, closing recently at $3.79. Despite a significant revenue of $66.41 million, the company reported a net loss of $559.78 million, leading to a market valuation of approximately $1.91 billion. The stock has shown short-term momentum with a 25.91% increase over the past week and an 11.80% rise over the last month, contrasting with a year-to-date decline of 9.76%.Current market sentiment suggests that RXRX is perceived as ove









